BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 8862952)

  • 1. Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus.
    Nagi DK; Ali VM; Yudkin JS
    Diabet Med; 1996 Aug; 13(8):753-7. PubMed ID: 8862952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
    De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
    J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
    Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
    Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
    Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.
    Ponssen HH; Elte JW; Lehert P; Schouten JP; Bets D
    Clin Ther; 2000 Jun; 22(6):709-18. PubMed ID: 10929918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Diabet Med; 2009 Jun; 26(6):649-54. PubMed ID: 19538242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
    Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
    Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term effects of metformin in type 2 diabetes.
    Eriksson A; Attvall S; Bonnier M; Eriksson JW; Rosander B; Karlsson FA
    Diabetes Obes Metab; 2007 Jul; 9(4):483-9. PubMed ID: 17587390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of masoprocol on carbohydrate and lipid metabolism in a rat model of Type II diabetes.
    Reed MJ; Meszaros K; Entes LJ; Claypool MD; Pinkett JG; Brignetti D; Luo J; Khandwala A; Reaven GM
    Diabetologia; 1999 Jan; 42(1):102-6. PubMed ID: 10027587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
    Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.
    Bosi E; Camisasca RP; Collober C; Rochotte E; Garber AJ
    Diabetes Care; 2007 Apr; 30(4):890-5. PubMed ID: 17277036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
    Forst T; Anastassiadis E; Diessel S; Löffler A; Pfützner A
    Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of metformin treatment on erythrocyte insulin binding in normal weight subjects, in obese non diabetic subjects, in type 1 and type 2 diabetic patients.
    Rizkalla SW; Elgrably F; Tchobroutsky G; Slama G
    Diabete Metab; 1986 Aug; 12(4):219-24. PubMed ID: 3533670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.